Akttyva Therapeutics

Akttyva Therapeutics

Early Stage

HealthCare

HealthCare

Overview

Raised to Date: Raised: $700

Total Commitments ($USD)

Platform

Fundify

Start Date

03/12/2022

Close Date

07/31/2022

Min. Goal
$25,000
Max. Goal
$1,000,000
Min. Investment

$100

Security Type

SAFE

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$10,000,000

Discount

20%

Rolling Commitments ($USD)

Status
Not Funded
Reporting Date

07/30/2022

Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise

$5

# of Investors

5

Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2020

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Eastham, Massachusetts

Business Type

Growth

Akttyva Therapeutics, with a valuation of $10 million, is raising funds on Fundify. It is a biotechnology company working on developing a cure for Acute Respiratory Distress Syndrome (ARDS). ARDS is the common cause of death in pneumonia, flu, and COVID-19; thus, by finding the cure for ARDS, Akttyva Therapeutics aims to convert COVID-19 to the common cold. The first product of Akttyva Therapeutics, AKT-001, is in human safety Phase 1 trial and is patent protected. Katya Tsaioun and Lana Gladstein founded Akttyva Therapeutics in October 2020. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1,000,000. The campaign proceeds will be used for clinical trials.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$1,148

$0

 

 

Net Income

$-37,738

$-4,409

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$420,402

$4,423

Accounts Receivable

$0

$0

Total Assets

$420,402

$4,423

Short-Term Debt

$234,122

$555

Long-Term Debt

$200,000

$0

Total Liabilities

$434,122

$555

Financials as of: 03/12/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Akttyva Therapeutics 07/30/2022 Fundify $10,000,000 $700 SAFE Not Funded RegCF
Akttyva Therapeutics 03/11/2022 Fundify $10,000,000 $27,750 SAFE Funded Test the Waters
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Akttyva Therapeutics on Fundify 2022
Platform: Fundify
Security Type: SAFE
Valuation: $10,000,000

Follow company

Follow Akttyva Therapeutics on Fundify 2022

Buy Akttyva Therapeutics's Deal Report

Warning: according to the close date for this deal, Akttyva Therapeutics may no longer be accepting investments.

Akttyva Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Akttyva Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Akttyva Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Akttyva Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge